Opigolix (INN , USAN ; developmental code name ASP-1707) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which was under development by Astellas Pharma for the treatment of endometriosis and rheumatoid arthritis.[1][2] It was also under investigation for the treatment of prostate cancer.[1] It reached phase II clinical trials for both endometriosis and rheumatoid arthritis prior to the discontinuation of its development in April 2018.[1]
![]() | |
Clinical data | |
---|---|
Other names | ASP-1707 |
Routes of administration | By mouth |
Drug class | GnRH modulator; GnRH antagonist; Antigonadotropin |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C25H19F3N4O5S |
Molar mass | 544.51 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ a b c "Opigolix - Astellas Pharma - AdisInsight".
- ^ Ezzati M, Carr BR (2015). "Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain". Women's Health. 11 (1): 19–28. doi:10.2217/whe.14.68. PMID 25581052.
External links
edit